Johnson & Johnson is a Hall of Fame company.
Johnson & Johnson launched the Maternal-Fetal Immune Disorders QuickFire Challenge: Innovating for Health Equity in March 2022, partnering with the Office of the Chief Medical Officer (OCMO) Health of Women team and Janssen Research & Development.
The QuickFire Challenge was launched to catalyze a search for solutions to improve the health of moms and babies of all backgrounds, as well as to limit the healthcare disparities that surround pregnancy.
Pregnancy can be a stressful time, but no one should worry about it being fatal. Around 700 women in the U.S. die from pregnancy-related complications each year, with the greatest risk shown in Black, Indigenous and people of color (BIPOC) — who are two to three times more likely to die from complications in pregnancy than white women.
With Johnson & Johnson’s QuickFire Challenge, applicants were able to submit their ideas for how to reduce the impact of immune-mediated diseases of pregnancy on historically underserved communities. Two awardees were named in late 2022, Acclinate and NX Prenatal Inc.
Both awardees received funding from a grant pool of $500,000. They also were given membership in the global Johnson & Johnson Innovation network.
Read more at jnj.com.
